Ignite Creation Date:
2024-05-06 @ 8:11 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02681978
Status:
COMPLETED
Last Update Posted:
2016-02-15
First Post:
2016-02-04
Brief Title:
Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease
Sponsor:
Campus Bio-Medico University
Organization:
Campus Bio-Medico University
Study Overview
Official Title:
Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease the RIVENDEL Study
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIVENDEL
Brief Summary:
This study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease CAD after complete revascularization with percutaneous coronary angioplasty PCI At least 30 days after PCI patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None